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ABSTRACT mecA-positive Staphylococcus aureus isolates phenotypically susceptible
to cefoxitin (mecA-methicillin-sensitive S. aureus [MSSA]) have been identiﬁed. We
describe the treatment and outcomes among patients with mecA-MSSA bloodstream
infections (BSI) and MRSA BSI matched 1:1 for age, BSI origin, and BSI type (n  17
per group). Compared to MRSA BSI patients, mecA-MSSA BSI patients more often ex-
perienced clinical failure (58.8% and 11.8%, P  0.010), driven largely by persistent
bacteremia (35.3% and 11.8%). mecA-MSSA BSI patients may be at higher risk for
poor clinical outcomes.
KEYWORDS bacteremia, mecA PCR, mecA-positive methicillin-susceptible S. aureus,
methicillin-resistant S. aureus, vancomycin
mecA-positive Staphylococcus aureus isolates (detected using molecular diagnosticassays) that exhibit cefoxitin susceptibility (mecA-methicillin-sensitive S. aureus
[MSSA]) are being reported with increasing frequency; approximately 3% of S. aureus
isolates may be mecA-MSSA (1). This phenotypic/genotypic discrepancy is concerning
and may lead to the mischaracterization of methicillin susceptibility, which could
expose patients to inferior antibiotic therapy (e.g., vancomycin for MSSA). We sought to
characterize the treatment and outcomes of mecA-MSSA bloodstream infections (BSI)
using methicillin-resistant S. aureus (MRSA) BSI as a comparator.
This was a retrospective comparative study of adult patients with mecA-MSSA and
MRSA BSI within a single health system from 1 January 2010 through 30 August 2015.
Patients 18 years of age, with polymicrobial BSI, who had an initial vancomycin MIC
of 2 mg/liter, and/or who lacked 30-day follow up were excluded. Patients with
mecA-MSSA BSI were matched 1:1 with MRSA BSI patients based on the following
criteria shown to be predictive of mortality in S. aureus bacteremia: age (15 years),
primary type of BSI, and origin of bacteremia (2). mecA-MSSA was deﬁned as an S.
aureus isolate possessing detectable mecA by a modiﬁed commercial PCR assay (BD
GeneOhm StaphSR assay; BD Diagnostics, Sainte-Foy, Quebec, Canada) but suscepti-
bility to oxacillin (MIC, 2 mg/liter) by automated susceptibility testing (Vitek 2;
bioMérieux, Durham, NC) and cefoxitin disk diffusion (zone of inhibition, 22 mm) (3,
4). MRSA was deﬁned as S. aureus with an automated oxacillin MIC of 2 mg/liter,
conﬁrmed by cefoxitin disk diffusion (zone of inhibition, 21 mm), and detectable
mecA by a modiﬁed commercial PCR assay (3, 4).
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Primary BSI type was classiﬁed as infective endocarditis (using the modiﬁed Duke
criteria), uncomplicated bacteremia, or complicated bacteremia (5, 6). Uncomplicated
bacteremia was deﬁned by the isolation of mecA-MSSA or MRSA from blood cultures
in patients without endocarditis, without implanted prostheses, having negative
follow-up blood cultures obtained 2 to 4 days after the index culture, defervescence
within 72 h of initiating effective therapy, and no evidence of metastatic sites of
infection (5, 7). Patients not meeting the deﬁnition for uncomplicated BSI or infective
endocarditis were classiﬁed as complicated BSI (5, 6). The source of bacteremia and
severity of illness (Pitt bacteremia score) were categorized as previously described (8, 9).
Clinical failure was a composite endpoint that included 30-day mortality, persistent
bacteremia (7 days), and/or change of intravenous antibiotic(s) or addition of a
second antibiotic targeted against mecA-MSSA or MRSA necessitated by a lack of
infection resolution. Secondary outcomes of interest included length of stay and
nephrotoxicity, as deﬁned by the vancomycin consensus guidelines (10). This study was
approved by the Wheaton Franciscan Healthcare institutional review board and was
conducted in accordance with the Declaration of Helsinki. Continuous variables were
summarized using the mean and standard deviation (SD) or the median and interquar-
tile range (IQR). Two-sample t tests or Wilcoxon rank sum tests were used to compare
the two groups. Categorical variables were summarized using frequencies and percent-
ages and compared between the two groups using the likelihood ratio 2 or Fisher’s
exact test.
Twenty-six patients with mecA-MSSA BSI were identiﬁed. Of these, nine patients
were excluded on the basis of: age (n 1), irretrievable data in the medical record (n
7), and insufﬁcient follow-up data (n  1). The 17 remaining mecA-MSSA patients were
successfully matched with a MRSA BSI comparator (n  34 total patients). No major
differences between the two study groups in baseline characteristics were observed
(Table 1). The proportion of patients with renal disease, a strong predictor of mortality
in S. aureus bacteremia, was 29.4% in both groups; however, there were more patients
on intermittent hemodialysis in the MRSA group (3 versus 1, respectively; P 0.601) (2).
All patients in the study were treated by an infectious diseases physician, and 94.1% of
the patients received empirical vancomycin therapy in both groups.
Patients with mecA-MSSA BSI were more likely to experience clinical failure than
those with MRSA BSI (58.8% versus 11.8%, respectively; P  0.010), and patients with
mecA-MSSA BSI tended to experience persistent bacteremia (35.3% versus 11.8%,
respectively; P  0.225). Salvage antibiotic therapy was employed in 10 (58.8%) and 2
(11.8%) of patients in the mecA-MSSA and MRSA groups, respectively (Table 2). Com-
bination antibiotic therapy was used as salvage therapy in all of these cases, with the
exception of one patient with mecA-MSSA BSI who received ceftaroline monotherapy.
The median length of stay and infection-related length of stay both trended longer for
the mecA-MSSA group than for the MRSA group. Nephrotoxicity was observed more
frequently in the mecA-MSSA group than in the MRSA group (23.5% versus 0%,
respectively; P  0.100), despite similar rates of renal disease between groups.
In the current study, patients with mecA-MSSA bacteremia experienced clinical
failure more often than matched patients with MRSA bacteremia. Failure was primarily
driven by persistent bacteremia in the mecA-MSSA group, but clinical outcomes, such
as mortality and length of stay, were similar between groups. Nearly all patients who
experienced failure had complicated BSI. Given the well-matched groups, this differ-
ence in clinical failure is unlikely due to host-level factors, although it could be a result
of an unmeasured host factor. It remains more plausible, based on our observations,
that either vancomycin monotherapy contributed to the delayed bacterial clearance
observed in themecA-MSSA group, or intrinsic virulence differences between these two
strains of S. aureus led to longer durations of bacteremia in the mecA-MSSA group.
These results expose yet another limitation of vancomycin monotherapy for the
treatment of MRSA bacteremia.
Almost allmecA-MSSA patients received vancomycin initially, likely because the CLSI
recommends reporting mecA-positive S. aureus as cefoxitin resistant. During the study
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TABLE 1 Patient demographics, clinical characteristics, antibiotic treatment, and clinical
outcomesa
Variable
Treatment group
P value
mecA-MSSA
(n  17)
MRSA
(n  17)
Baseline characteristics
Age (mean  SD) (yr) 66 15 63 18 0.642
Male 12 (70.6) 9 (52.9) 0.481
Race 0.999
Caucasian 14 (82.4) 12 (76.5)
Other 3 (17.6) 4 (23.5)
Source of bacteremia 0.913
Bone/joint 6 (35.3) 6 (35.3)
Skin and skin structure 6 (35.3) 5 (29.4)
Otherb 5 (29.4) 6 (35.3)
Past medical history
Previous hospitalization 7 (42.2) 11 (64.7) 0.303
Previous surgery 3 (17.6) 4 (23.5) 0.999
Previous S. aureus infection 0 (0) 2 (11.8) 0.485
Injection drug use 1 (5.9) 2 (11.8) 0.999
Prosthesis 9 (52.9) 5 (29.4) 0.296
Renal disease 5 (29.4) 5 (29.4) 0.999
Hemodialysis 1 (5.9) 3 (17.6) 0.601
Liver disease 2 (11.8) 0 (0) 0.485
Congestive heart failure 8 (47.1) 6 (35.3) 0.728
Diabetes mellitus 10 (58.8) 8 (47.1) 0.732
Cancer 3 (17.6) 1 (5.9) 0.601
Antibiotic exposures within 30 days of
hospitalization
3 (17.6) 6 (35.3) 0.438
Pitt bacteremia score (median [IQR]) 1.0 (0, 2.5) 1.0 (0, 2.0) 0.683
Complicated bacteremia 8 (47.0) 8 (47.0) 0.999
Vancomycin MIC (median [IQR]) (mg/liter) 1.0 (0.5, 1.0) 0.5 (0.5, 1.0) 0.563
Vancomycin MIC90 (mg/liter) 1.0 1.0
Oxacillin MIC90 (mg/liter) 0.5 4.0
Concomitant site(s) of S. aureus infection 10 (58.8) 8 (47.0) 0.721
Procedure performed to mitigate complications of S.
aureus bacteremia
9 (52.9) 10 (58.8) 0.999
Antibiotic therapy
Vancomycin 16 (94.1) 16 (94.1) 0.999
Initial vancomycin trough (median [IQR]) (mg/liter) 12.9 (9.73, 18.48) 12.9 (10, 15) 0.696
Time to therapeutic vancomycin trough (median [IQR])
(days)c
4 (3, 8) 5 (3, 7) 0.796
Change in antistaphylococcal therapy 14 (82.4) 10 (58.8) 0.259
No. of changes in antistaphylococcal therapy (median
[IQR])
1 (0, 2) 0 (0, 0.5) 0.007
Use of salvage antibiotic therapy 10 (58.8) 2 (11.8) 0.010
Salvage antibiotic therapy type 0.999
Combination antibiotic therapy 9 (90.0) 2 (100)
Ceftaroline monotherapy 1 (10.0) 0 (0)
Clinical outcomes
Clinical failured 10 (58.8) 2 (11.8) 0.010
30-day, all-cause mortality 1 (5.9) 1 (5.9) 0.999
Persistent bacteremia (7 days) 6 (35.3) 2 (11.8) 0.225
Change in antibiotic therapy due to lack of infection
resolution
10 (58.8) 1 (5.9) 0.002
Duration of bacteremia (median [IQR]) (days) 3.5 (1.25, 7.75) 3 (3, 5) 0.901
Bacteremia clearance on vancomycin monotherapy 5 (29.4) 13 (76.5) 0.015
Recurrence of S. aureus infection within 1 yr 0 (0) 2 (11.8) 0.484
Readmission within 60 days of initial hospital
discharge
6 (35.3) 6 (35.3) 0.999
Length of stay (median [IQR]) (days) 16 (10, 21) 14 (9, 18) 0.496
Infected-related length of stay (median [IQR]) (days) 14 (9, 18) 11 (9, 16) 0.357
Nephrotoxicity 4 (23.5) 0 (0) 0.103
aAll data presented are as no. (%), unless otherwise noted. IQR, interquartile range.
bIncludes endocarditis, intravenous catheter, genitourinary, central nervous system, and unknown source.
cTherapeutic serum vancomycin trough, 15 to 20 mg/liter.
dClinical failure was a composite deﬁnition of 30-day, all-cause mortality, persistent bacteremia (7 days),
and/or change in antibiotic therapy due to lack of infection resolution; some patients met more than one
clinical failure criterion.
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period, physicians were notiﬁed of positive mecA PCR results before susceptibility data
became available. Antibiotic selection after vancomycin varied in this group, and the
majority of patients improved on these regimens (Table 2). It is notable that of the 10
patients who experienced failure, all but one had complicated BSI. A higher bacterial
inoculum is likely with complicated bacteremia, especially infective endocarditis (11).
Given the 107 reversion rate from mecA-MSSA to MRSA demonstrated by Proulx and
colleagues, there may be more MRSA involved with complicated mecA-MSSA infections
(1). Our results do not demonstrate that the initial use of a -lactam in combination
with vancomycin or daptomycin improved outcomes for mecA-MSSA patients, but for
complicated mecA-MSSA bacteremia, especially infective endocarditis, combination
antibiotic therapy targeting MRSA and MSSA may be warranted. Additionally, cefoxitin
has afﬁnity for the low-molecular-weight penicillin-binding protein 4 (PBP4). PBP4
overexpression in S. aureus results in highly cross-linked cell walls and elevated
-lactam MICs (12). Conversely, lesser cross-linked S. aureus cell walls are associated
with elevated vancomycin MICs (13). The cefoxitin-susceptible phenotype of the mecA-
MSSA isolates may represent both reduced expression of PBP4 and vancomycin toler-
ance; interestingly, the median vancomycin MIC was higher in the mecA-MSSA group
than the MRSA group. Given that the majority of patients in both groups received initial
therapy with vancomycin, the difference in vancomycin MICs between groups may also
explain the observed difference in persistent bacteremia between groups.
Our study is limited by its retrospective design, small sample, and restriction to a
single health system in one geographic area of the United States. Additionally, bacterial
isolates were not secured for additional laboratory analyses, nor did we have dapto-
mycin and ceftaroline MICs for these isolates. However, the collected microbiological
data represent what is available to clinicians, and this is the ﬁrst clinical evaluation of
mecA-MSSA to include more than two patients from a single center (1, 14). We believe
these results should prove informative for clinicians confronted with mecA-MSSA BSI. It
is clear from these data that the treatment of mecA-MSSA poses a unique challenge for
infectious diseases clinicians and requires additional attention.
In summation, mecA PCR testing and the potential for a discrepancy between
genotypic and phenotypic cefoxitin resistance results among S. aureus isolates have
further complicated the treatment of S. aureus BSI. The description of mecA-positive S.
aureus as cefoxitin resistant should be reevaluated, as this may predispose patients to
vancomycin therapy, especially if physicians are notiﬁed of mecA PCR results before
susceptibility results. Our data suggest that vancomycin monotherapy for mecA-MSSA
BSI may place patients at risk for clinical failure.
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